迈百瑞IPO折戟 关联交易等问题待解

北京商报
19 Feb

荣昌生物正值多事之秋,核心技术人员相继离职之后,关联公司烟台迈百瑞国际生物医药股份有限公司(以下简称“迈百瑞”)的创业板上市也宣告终止。2月18日,北京商报记者从深交所获悉,迈百瑞首次公开发行股票并在创业板上市的审核已正式终止。迈百瑞的IPO进程历时近两年半,其申请于2022年9月28日获受理,2023年6月16日成功过会,但此后一直未提交注册,直至审核被终止。在此次上市折戟背后,迈百瑞招股材料中...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10